Activating mutations in the KRAS gene (Kirsten rat sarcoma 2 viral oncogene 
homolog gene) are commonly seen across the various solid organ and 
hematolymphoid neoplasms. With the likelihood of the mutation specific KRAS 
inhibitor entering clinical practice, the present studies profiled the landscape 
of these mutations in the Indian population to add to databases and posit the 
clinical utility of its emerging inhibitors. This study included 489 formalin 
fixed paraffin-embedded (FFPE) tissue samples from consecutive patients during a 
5-year period (2015-2019). The clinical records were obtained from the medical 
record archives of the institution. Library preparation was done using the 
Oncomine Assay™. Sequencing was performed using the Ion PGM Hi-Q Sequencing Kit 
on the Ion Torrent Personal Genome Machine (Ion PGM) as well as on Ion Torrent 
S5 sequencer using the S5 sequencing kit. Ion Torrent Suite™ Browser version 
5.10 and Ion Reporter™ version 5.10 were used for data analysis. A total of 50 
cases with KRAS mutations were observed occurring most commonly in the codons 12 
and 13. The G12D mutation was the most commonly encountered subtype in our 
cohort (21/50), whereas the G12C mutation was observed in 5 cases, and 
interestingly, this mutation was only seen in patients with non-small cell lung 
carcinoma (NSCLC). In the largest cohort from Indian subcontinent reporting 
spectrum of KRAS mutations in human cancers, an incidence of 11% was observed 
across all cancer types. Therapies targeting the G12C mutations can benefit up 
to 20% KRAS-mutated NSCLC. Building databases of spectrum of KRAS mutations in 
different populations across diverse cancer types is the anticipatory step to 
this end.